Massive Bio
New York, New York, United States
Massive Bio’s vision is to transform the entire pharmaceutical value chain with disruptive solutions that enhance the ecosystem from drug development to commercialization. As a unique AI-enabled real-world data company, Massive Bio addresses all friction points in the end-to-end patient journey, facilitating patient access to advanced treatment options and optimizing drug clinical trials and commercialization for pharmaceutical companies. Committed to breaking down barriers and enhancing equitable access to clinical trials, Massive Bio fosters value-based oncology decisions and facilitates data-driven cancer treatment. Founded in 2015 by a team of clinical, technology, and M&A executives, Massive Bio has served over four dozen pharmaceutical companies, contract research organizations, and hospital networks. It is a founding member of the CancerX public-private partnership and participates in the Cancer Moonshot White House initiative.
Only accessible to MedStartr community members.
Join nowCompany Info
- Founded
- 2015
- Website
- massivebio.com/
Categories
Disease Areas
Technologies
Only accessible to MedStartr community members.
Join nowWhat do you think of Massive Bio?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now